ECSP18048718A - Imidazolilimidazoles condensados como compuestos antivirales - Google Patents

Imidazolilimidazoles condensados como compuestos antivirales

Info

Publication number
ECSP18048718A
ECSP18048718A ECSENADI201848718A ECDI201848718A ECSP18048718A EC SP18048718 A ECSP18048718 A EC SP18048718A EC SENADI201848718 A ECSENADI201848718 A EC SENADI201848718A EC DI201848718 A ECDI201848718 A EC DI201848718A EC SP18048718 A ECSP18048718 A EC SP18048718A
Authority
EC
Ecuador
Prior art keywords
imidazolylimidazoles
condensed
compounds
antiviral compounds
administration
Prior art date
Application number
ECSENADI201848718A
Other languages
English (en)
Inventor
Elizabeth Bacon
Evan Krygowski
Martin Teresa Trejo
Darryl Kato
Jeromy Cottell
Ashley Katana
Chinh Viet Tran
Sheila Zipfel
John Link
James Taylor
Zheng-Yu Yang
Original Assignee
Gilead Pharmasset Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47324426&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP18048718(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Pharmasset Llc filed Critical Gilead Pharmasset Llc
Publication of ECSP18048718A publication Critical patent/ECSP18048718A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La descripción se refiere a compuestos anti-virales, composiciones que contienen tales compuestos, y métodos terapéuticos que incluyen la administración de tales compuestos, así como a procesos e intermediarios útiles para preparar tales compuestos.
ECSENADI201848718A 2011-11-16 2018-06-27 Imidazolilimidazoles condensados como compuestos antivirales ECSP18048718A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161560654P 2011-11-16 2011-11-16

Publications (1)

Publication Number Publication Date
ECSP18048718A true ECSP18048718A (es) 2018-07-31

Family

ID=47324426

Family Applications (2)

Application Number Title Priority Date Filing Date
ECSP13012790 ECSP13012790A (es) 2011-11-16 2013-07-25 Imidazolilimidazoles condensados como compuestos antivirales
ECSENADI201848718A ECSP18048718A (es) 2011-11-16 2018-06-27 Imidazolilimidazoles condensados como compuestos antivirales

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ECSP13012790 ECSP13012790A (es) 2011-11-16 2013-07-25 Imidazolilimidazoles condensados como compuestos antivirales

Country Status (37)

Country Link
US (14) US20130164260A1 (es)
EP (4) EP3778606A3 (es)
JP (5) JP6082749B2 (es)
KR (5) KR20190121406A (es)
CN (2) CN105837584B (es)
AP (1) AP2013006877A0 (es)
AU (1) AU2012318253B8 (es)
BR (1) BR112013012091A2 (es)
CA (2) CA2815082C (es)
CL (1) CL2013001428A1 (es)
CO (1) CO6791562A2 (es)
CR (1) CR20130231A (es)
CY (2) CY1116987T1 (es)
DK (2) DK2635588T3 (es)
EA (4) EA023644B1 (es)
EC (2) ECSP13012790A (es)
ES (3) ES2544107T3 (es)
HK (1) HK1188989A1 (es)
HR (2) HRP20150725T1 (es)
HU (2) HUE039966T2 (es)
IL (5) IL226345A (es)
LT (1) LT2907816T (es)
MA (1) MA34727B1 (es)
MD (2) MD4521C1 (es)
ME (1) ME02196B (es)
MX (3) MX346729B (es)
MY (1) MY173045A (es)
PE (2) PE20141163A1 (es)
PH (1) PH12015502839B1 (es)
PL (3) PL2907816T3 (es)
PT (3) PT2907816T (es)
RS (2) RS54207B1 (es)
SG (1) SG10201700947UA (es)
SI (3) SI2907816T1 (es)
SM (1) SMT201500197B (es)
UA (2) UA119437C2 (es)
WO (1) WO2013075029A1 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0410846B8 (pt) 2003-05-30 2021-05-25 Gilead Pharmasset Llc nucleosídeo e composição farmacêutica compreendendo o mesmo
TW202042807A (zh) 2009-05-13 2020-12-01 美商基利法瑪席特有限責任公司 抗病毒化合物
CA2817840A1 (en) 2010-11-17 2012-05-24 Gilead Sciences, Inc. Antiviral compounds
WO2013007106A1 (zh) 2011-07-09 2013-01-17 广东东阳光药业有限公司 作为丙型肝炎病毒抑制剂的螺环化合物
AU2012308295B2 (en) 2011-09-16 2017-10-26 Gilead Pharmasset Llc Methods for treating HCV
SI2907816T1 (sl) * 2011-11-16 2018-10-30 Gilead Pharmasset Llc Kondenzirani imidazolilimidazoli kot protivirusni sestavki
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20130309196A1 (en) * 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
LT2950786T (lt) 2013-01-31 2020-03-10 Gilead Pharmasset Llc Dviejų antivirusinių junginių preparatų kompozicija
JP5614568B1 (ja) 2013-02-07 2014-10-29 保土谷化学工業株式会社 ジアザトリフェニレン環構造を有する化合物および有機エレクトロルミネッセンス素子
US20140343008A1 (en) * 2013-05-16 2014-11-20 Gilead Pharmasset Llc Hepatitis c treatment
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
JP6333372B2 (ja) * 2013-07-09 2018-05-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤の組み合わせ
WO2015009744A1 (en) 2013-07-17 2015-01-22 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of hcv
ES2792503T3 (es) 2013-08-27 2020-11-11 Gilead Pharmasset Llc Formulación combinada de dos compuestos antivirales
WO2015030854A1 (en) 2013-08-27 2015-03-05 Gilead Pharmasset Llc Solid dispersion formulation of an antiviral compound
CN104418784B (zh) * 2013-09-04 2019-02-19 浙江九洲药业股份有限公司 一种抗病毒药物中间体的拆分方法
ES2708993T3 (es) 2013-12-23 2019-04-12 Gilead Sciences Inc Formas cristalinas de un tripéptido macrocíclico inhibidor de NS3 del VHC
TW202014413A (zh) * 2014-06-11 2020-04-16 美商基利法瑪席特有限責任公司 製備抗病毒化合物之方法
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
BR112017013858A2 (pt) 2014-12-26 2018-02-27 Univ Emory n4-hidroxicitidina e derivados e usos antivirais relacionados aos mesmos
CN110372559A (zh) * 2014-12-29 2019-10-25 重庆博腾制药科技股份有限公司 一种(4S)-N-Boc-4--甲氧基甲基-L-脯氨酸的合成方法
CN104586802B (zh) * 2015-02-02 2018-01-16 长春海悦药业股份有限公司 一种含有索菲布韦的药物组合物
CN106008552B (zh) * 2015-03-01 2020-08-21 南京圣和药业股份有限公司 苯并[e]吡唑并[1,5-c][1,3]噁嗪类化合物及其应用
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2017060820A1 (en) * 2015-10-08 2017-04-13 Mylan Laboratories Limited Process for the preparation of velpatasvir
CN105294713A (zh) * 2015-10-09 2016-02-03 重庆康施恩化工有限公司 Velpatasvir中间体及其制备方法
CN105801553B (zh) * 2016-04-12 2018-06-19 爱斯特（成都）生物制药股份有限公司 一种苯并色烯衍生物的制备方法
CN106916134B (zh) * 2016-04-14 2020-04-17 苏州楚凯药业有限公司 一种10,11-二氢-5H-苯并[d]萘并[2,3-b]吡喃酮衍生物的制备方法
WO2017184670A2 (en) 2016-04-22 2017-10-26 Gilead Sciences, Inc. Methods for treating zika virus infections
EP3452038B1 (en) * 2016-05-05 2022-07-06 Laurus Labs Limited Process for the preparation of intermediates useful in the preparation of hepatitis c virus (hcv) inhibitors
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
EA201892375A1 (ru) 2016-05-27 2019-08-30 Джилид Сайэнс, Инк. Способы лечения инфекций, вызываемых вирусом гепатита b
BR102017011025A2 (pt) 2016-06-02 2017-12-19 Gilead Pharmasset Llc Formulation of combination of three antiviral compounds
CN108368123B (zh) * 2016-07-08 2021-02-19 深圳市塔吉瑞生物医药有限公司 一种取代的咪唑基化合物及其药物组合物
KR101887969B1 (ko) * 2016-08-30 2018-08-13 한국과학기술연구원 항바이러스 활성을 가지는 카르바졸 화합물
CN107573380B (zh) * 2016-11-30 2020-06-02 上海博志研新药物技术有限公司 维帕他韦中间体、制备方法及应用
CN106831737B (zh) * 2017-02-27 2020-03-17 上海众强药业有限公司 维帕他韦及其衍生物的制备
CN107501280A (zh) * 2017-09-05 2017-12-22 安徽华昌高科药业有限公司 一种维帕他韦的合成方法
US10849960B2 (en) 2017-09-08 2020-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synergistic combination of IL-4, interferon gamma, and interferon alpha in treating ovarian cancer
CN107655986B (zh) * 2017-09-08 2020-11-03 安徽一灵药业有限公司 一种维帕他韦有关物质的检测方法
WO2019113462A1 (en) 2017-12-07 2019-06-13 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
CN108276421B (zh) * 2018-02-13 2019-08-06 浙江永太药业有限公司 一种维帕他韦的合成方法
PT4045040T (pt) 2019-10-18 2023-06-30 Wockhardt Ltd Compostos bicíclicos contendo nitrogênio
CN111018870B (zh) * 2019-11-29 2021-07-23 南京正济医药研究有限公司 一种维帕他韦中间体的制备方法
CN110981879B (zh) * 2019-12-09 2021-03-05 南通常佑药业科技有限公司 一种制备ns5a抑制剂-维帕他韦的方法
CN113072615B (zh) * 2021-03-24 2023-01-10 上海法默生物科技有限公司 一种维帕他韦中间体的制备方法
CA3220903A1 (en) * 2021-05-21 2022-11-24 Gilead Sciences, Inc. Pentacyclic derivatives as zika virus inhibitors

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
CA2083386C (en) 1990-06-13 1999-02-16 Arnold Glazier Phosphorous prodrugs
ATE167679T1 (de) 1990-09-14 1998-07-15 Acad Of Science Czech Republic Wirkstoffvorläufer von phosphonaten
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
US5858389A (en) 1996-08-28 1999-01-12 Shaker H. Elsherbini Squalene is an antiviral compound for treating hepatitis C virus carriers
US6841566B2 (en) 2001-07-20 2005-01-11 Boehringer Ingelheim, Ltd. Viral polymerase inhibitors
MXPA05012101A (es) 2003-05-09 2006-02-08 Boehringer Ingelheim Int Bolsillo de union al inhibidor de polimerasa ns5b del virus de la hepatitis c.
US7157492B2 (en) 2004-02-26 2007-01-02 Wyeth Dibenzo chromene derivatives and their use as ERβ selective ligands
EP2316839B1 (en) 2004-07-16 2014-03-12 Gilead Sciences, Inc. Antiviral heterocyclic compounds having phosphonate groups
US8891379B2 (en) 2006-06-02 2014-11-18 Riverbed Technology, Inc. Traffic flow inference based on link loads and gravity measures
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) * 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2671975C (en) 2006-12-07 2013-10-29 Daiichi Sankyo Company, Limited Film-coated preparation having improved stability
US7741347B2 (en) 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5355594B2 (ja) * 2008-02-11 2013-11-27 クォルコム・メムズ・テクノロジーズ・インコーポレーテッド 干渉変調器の測定及び特性評価のための方法
CN101998952B (zh) 2008-02-12 2014-10-08 百时美施贵宝公司 丙型肝炎病毒抑制剂
US7704992B2 (en) 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8147818B2 (en) * 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5312486B2 (ja) 2008-02-13 2013-10-09 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルス阻害剤
US20100256184A1 (en) 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US8729077B2 (en) * 2008-11-28 2014-05-20 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
SG171891A1 (en) 2008-12-03 2011-07-28 Presidio Pharmaceuticals Inc Inhibitors of hcv ns5a
CA2753313A1 (en) * 2009-02-23 2010-08-26 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
BRPI1007836A2 (pt) 2009-02-27 2015-09-01 Enanta Phamaceuticals Inc Inibidores do vírus c da hepatite
EP2410841A4 (en) 2009-03-27 2012-10-24 Presidio Pharmaceuticals Inc SUBSTITUTED BICYCLIC HCV INHIBITORS
WO2010111534A1 (en) 2009-03-27 2010-09-30 Presidio Pharmaceuticals, Inc. Fused ring inhibitors of hepatitis c
WO2010132538A1 (en) 2009-05-12 2010-11-18 Schering Corporation Fused tricyclic aryl compounds useful for the treatment of viral diseases
TW202042807A (zh) 2009-05-13 2020-12-01 美商基利法瑪席特有限責任公司 抗病毒化合物
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP3006441A1 (en) * 2009-09-04 2016-04-13 Janssen Pharmaceuticals, Inc. Ns5a inhibitors
US9156818B2 (en) 2009-09-11 2015-10-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
CA2782024A1 (en) * 2009-11-25 2011-06-03 Schering Corporation Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
US8476225B2 (en) 2009-12-04 2013-07-02 Gilead Sciences, Inc. Antiviral compounds
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102791687B (zh) * 2009-12-18 2015-02-11 北京凯因科技股份有限公司 C型肝炎病毒复制的新型抑制剂
JP2013515068A (ja) * 2009-12-22 2013-05-02 メルク・シャープ・アンド・ドーム・コーポレーション ウイルス性疾患の治療のための縮合三環式化合物およびその使用方法
EA201290882A1 (ru) 2010-03-09 2013-04-30 Мерк Шарп Энд Домэ Корп. Конденсированные трициклические силильные соединения и способы их применения для лечения вирусных заболеваний
US9125904B1 (en) 2010-05-11 2015-09-08 Achillion Pharmaceuticals, Inc. Biphenyl imidazoles and related compounds useful for treating HCV infections
US20110312996A1 (en) 2010-05-17 2011-12-22 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
EP2963034A1 (en) 2010-08-26 2016-01-06 RFS Pharma, LLC. Potent and selective inhibitors of hepatitis c virus
WO2012048421A1 (en) 2010-10-14 2012-04-19 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
CA2817840A1 (en) 2010-11-17 2012-05-24 Gilead Sciences, Inc. Antiviral compounds
WO2012087976A2 (en) 2010-12-21 2012-06-28 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
SI2907816T1 (sl) 2011-11-16 2018-10-30 Gilead Pharmasset Llc Kondenzirani imidazolilimidazoli kot protivirusni sestavki
CN104010631B (zh) 2011-12-29 2016-08-17 艾伯维公司 包含hcv抑制剂的固体组合物
US20130309196A1 (en) 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
US9079887B2 (en) 2012-05-16 2015-07-14 Gilead Sciences, Inc. Antiviral compounds
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
WO2015030854A1 (en) 2013-08-27 2015-03-05 Gilead Pharmasset Llc Solid dispersion formulation of an antiviral compound
ES2792503T3 (es) 2013-08-27 2020-11-11 Gilead Pharmasset Llc Formulación combinada de dos compuestos antivirales
TW202014413A (zh) 2014-06-11 2020-04-16 美商基利法瑪席特有限責任公司 製備抗病毒化合物之方法
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
JP2016051146A (ja) 2014-09-02 2016-04-11 ウシオ電機株式会社 光検出装置

Also Published As

Publication number Publication date
EP2907816B1 (en) 2018-06-13
US20200071337A1 (en) 2020-03-05
EP2635588A1 (en) 2013-09-11
IL244122A0 (en) 2016-04-21
EP3778606A2 (en) 2021-02-17
US20130156732A1 (en) 2013-06-20
KR102036469B1 (ko) 2019-10-24
IL244124A0 (en) 2016-04-21
IL244123A0 (en) 2016-04-21
PL2907816T3 (pl) 2019-03-29
HK1188989A1 (en) 2014-05-23
KR20190121406A (ko) 2019-10-25
DK2635588T3 (en) 2015-09-07
US20210053981A1 (en) 2021-02-25
PT2635588E (pt) 2015-09-14
JP6082749B2 (ja) 2017-02-15
MD4521C1 (ro) 2018-05-31
US9051340B2 (en) 2015-06-09
EP2907816A1 (en) 2015-08-19
MX361735B (es) 2018-12-14
US20140112885A1 (en) 2014-04-24
MD4521B1 (ro) 2017-10-31
AU2012318253A1 (en) 2013-05-30
AU2012318253A8 (en) 2015-08-13
US9868745B2 (en) 2018-01-16
EP3778606A3 (en) 2021-03-03
CN105837584B (zh) 2018-07-13
HRP20181384T1 (hr) 2018-12-28
US8575135B2 (en) 2013-11-05
EA023644B1 (ru) 2016-06-30
US20150299213A1 (en) 2015-10-22
KR20200117043A (ko) 2020-10-13
US20130177530A1 (en) 2013-07-11
ME02196B (me) 2016-02-20
HUE027733T2 (en) 2016-10-28
NZ752834A (en) 2021-01-29
US20180186806A1 (en) 2018-07-05
EA201890333A1 (ru) 2018-10-31
NZ720856A (en) 2017-12-22
CO6791562A2 (es) 2013-11-14
NZ737924A (en) 2019-06-28
US9809600B2 (en) 2017-11-07
PE20171444A1 (es) 2017-09-29
US20130164260A1 (en) 2013-06-27
MD20130029A2 (en) 2013-09-30
MD20150091A2 (ro) 2016-02-29
SI2907816T1 (sl) 2018-10-30
EA037883B1 (ru) 2021-05-31
CA2884712A1 (en) 2013-05-23
SI2635588T1 (sl) 2015-10-30
CA2815082C (en) 2015-07-07
AP2013006877A0 (en) 2013-05-31
MD4403C1 (ro) 2016-09-30
KR20180095119A (ko) 2018-08-24
JP2016199593A (ja) 2016-12-01
PL2635588T3 (pl) 2015-10-30
US8940718B2 (en) 2015-01-27
MY173045A (en) 2019-12-20
CY1121225T1 (el) 2020-05-29
EP3431477B1 (en) 2020-10-14
ECSP13012790A (es) 2013-10-31
EA201390576A1 (ru) 2013-11-29
MX346729B (es) 2017-03-30
CY1116987T1 (el) 2017-04-05
CN103328480B (zh) 2016-05-25
JP2015512860A (ja) 2015-04-30
US8921341B2 (en) 2014-12-30
AU2012318253B8 (en) 2015-08-13
DK2907816T3 (en) 2018-09-24
KR20140096239A (ko) 2014-08-05
MX2020010330A (es) 2020-10-22
IL226345A (en) 2016-03-31
HUE039966T2 (hu) 2019-02-28
WO2013075029A1 (en) 2013-05-23
SG10201700947UA (en) 2017-03-30
NZ610525A (en) 2017-05-26
CL2013001428A1 (es) 2014-06-27
JP2018024705A (ja) 2018-02-15
IL252345A0 (en) 2017-07-31
JP2019206597A (ja) 2019-12-05
US20190276468A1 (en) 2019-09-12
EP2635588B1 (en) 2015-06-10
EA030941B1 (ru) 2018-10-31
CN103328480A (zh) 2013-09-25
US9221833B2 (en) 2015-12-29
US10807990B2 (en) 2020-10-20
CN105837584A (zh) 2016-08-10
PH12015502839A1 (en) 2019-05-15
PL3431477T3 (pl) 2021-04-06
US20140309432A1 (en) 2014-10-16
EA201591244A1 (ru) 2016-02-29
PE20141163A1 (es) 2014-09-21
EP3431477A1 (en) 2019-01-23
CA2815082A1 (en) 2013-05-23
RS54207B1 (en) 2015-12-31
PT3431477T (pt) 2020-12-15
IL252345B (en) 2022-01-01
SI3431477T1 (sl) 2021-01-29
UA110354C2 (uk) 2015-12-25
ES2687291T3 (es) 2018-10-24
EA202190619A1 (ru) 2021-09-30
UA119437C2 (uk) 2019-06-25
US20180244683A1 (en) 2018-08-30
US20170145027A1 (en) 2017-05-25
HRP20150725T1 (hr) 2015-08-14
MD4403B1 (ro) 2016-02-29
PH12015502839B1 (en) 2020-10-30
ES2843023T3 (es) 2021-07-15
KR101890400B1 (ko) 2018-08-21
KR20210043734A (ko) 2021-04-21
US20150141326A1 (en) 2015-05-21
LT2907816T (lt) 2018-09-10
CR20130231A (es) 2013-09-19
IL226345A0 (en) 2013-07-31
PT2907816T (pt) 2018-10-18
RS57638B1 (sr) 2018-11-30
SMT201500197B (it) 2015-09-07
MA34727B1 (fr) 2013-12-03
KR102241651B1 (ko) 2021-04-20
ES2544107T3 (es) 2015-08-27
AU2012318253B2 (en) 2015-08-06
MX2013005575A (es) 2013-09-05
US20160083394A1 (en) 2016-03-24
BR112013012091A2 (pt) 2019-09-10
JP2021001230A (ja) 2021-01-07

Similar Documents

Publication Publication Date Title
ECSP18048718A (es) Imidazolilimidazoles condensados como compuestos antivirales
CR20150370A (es) Compuestos antivirales
ECSP11011517A (es) Compuestos antivirales
UY33735A (es) Compuestos antivirales
CR20160119A (es) Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística
AR091837A1 (es) Compuestos para inmunoterapia dirigida
CR20210079A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
GT201400195A (es) Compuestos de heterociclilo como inhibidores de mek
IN2014MN02496A (es)
CL2015000956A1 (es) Compuestos derivados de pirrolotriazinona como inhibidores de pi3k; composicion farmaceutica que los comprende; combinacion farmaceutica; uso para tratar enfermedades respiratorias, autoinmunes, trastornos neurologicos, cardiovasculares, metabolicos, entre otros.
EA201790963A1 (ru) Противовирусные соединения
CR20150271A (es) Peptidos como agonistas de oxitocina
CR20160072A (es) Compuestos y composiciones como inhibidores de la mek
CR20140435A (es) Nuevos derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos
DOP2013000307A (es) Antagonistas de trpv4
CR20140257A (es) Nuevos 2h-indazoles como antagonistas del receptor ep2
CO6321288A2 (es) Sales de compuestos inhibidores de vih
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
GT201200328A (es) Intermedios de agomelatina y método de preparación de éstos
DOP2015000007A (es) Métodos para preparar triazolopiridinas sutituidas
CR20150160A (es) Derivados de macrólidos, su preparación y su uso terapéutico
CR20150028A (es) Derivados de ariletinilo
CR20140531A (es) Derivados de ariletinilo
CU20150015A7 (es) Tris-(hetero)aril-pirazoles y su uso
CO7141428A2 (es) Proceso para la elaboración de undecapéptidos cíclicos